Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, making ...
Antidepressants known as selective serotonin reuptake inhibitors, or SSRIs have been the first line of treatment for mood disorders and anxiety for the last three decades. These medicines mainly ...